Compare Stocks

Advent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets in North America, Europe, and Asia. It develops, manufactures, and assembles fuel cell systems and critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers high-temperature proton exchange membrane (HT-PEM) fuel cells, including membrane electrode assemblies, bipolar plates, and reformers, as well as provides fuel-cell stack assembly and testing services. It serves stationary power, portable power, automotive, aviation, energy storage, and sensor markets. The company is headquartered in Boston, Massachusetts.

Aurania Resources Ltd., a junior exploration mining company, engages in the identification, evaluation, acquisition, and exploration of mineral properties in Ecuador and Peru. The company explores for gold, silver, copper, and other precious metal deposits. Its flagship project is the 100% owned Lost Cities Cutucu project comprises 42 mineral exploration concessions covering an area of approximately 207,764 hectares located in southeastern Ecuador. The company was formerly known as Urania Resources Ltd. and changed its name to Aurania Resources Ltd. in March 2012. Aurania Resources Ltd. was founded in 2001 and is headquartered in Toronto, Canada.

Falco Resources Ltd. engages in the exploration, evaluation, and development of mineral properties in Canada. It explores for base and precious metals, as well as gold, zinc, copper, and silver deposits. The company owns mining claims and contractual rights in relation to mining concessions covering an area of approximately 70,000 hectares of land in the Rouyn-Noranda mining camp located in the Province of Québec. Its principal asset includes the Horne 5 Project located in the former Horne mine. The company was formerly known as Falco Pacific Resource Group Inc. and changed its name to Falco Resources Ltd. in July 2014. Falco Resources Ltd. was incorporated in 2010 and is headquartered in Montreal, Canada.

OPENLANE, Inc., together with its subsidiaries, operates as a digital marketplace for used vehicles, which connects sellers and buyers in North America, Europe, the Philippines, and Uruguay. The company operates through two segments, Marketplace and Finance. The Marketplace segment offers digital marketplace services for buying and selling used vehicles. Its digital marketplaces include OPENLANE, a mobile-app enabled solutions that allows dealers to sell and source inventory in the United States. This segment also provides value-added ancillary services, including inbound and outbound transportation logistics, reconditioning, vehicle inspection and certification, titling, administrative, and collateral recovery services. This segment sells its products and services through vehicle manufacturers, fleet companies, rental car companies, finance companies, and others. The Finance segment offers floorplan financing, a short-term inventory-secured financing to independent used vehicle dealers. The company serves commercial customers and dealer customers. The company was formerly known as KAR Auction Services, Inc. and changed its name to OPENLANE, Inc. in May 2023. OPENLANE, Inc. was incorporated in 2006 and is headquartered in Carmel, Indiana.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.